Developmental Therapeutics—Immunotherapy

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
 
 
Eglys Gonzalez Marcano, Leona Kröhle, Joachim Ahlers, et al.
 
The abstract concludes: 
This study have confirmed an anti-tumor response in the majority of patients treated, with none to very low side effects and a good quality of life during the treatment. To obtain more detailed and significant data on the efficacy of this therapy, a further controlled clinical phase study should be performed.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Wolfgang Wick, Antje Wick, Olivier L. Chinot, et al.
 
The abstract concludes: 
VXM01 in combination with avelumab was safe and produces detectable peripheral VEGFR-2 specific immune responses. Three patients had an objective response. Clinical trial information: NCT03750071.

-------------------------------------------------------------------------------------------------------------------------------------------------------

 
Rodney Paul Rocconi, Erin E. Stevens, Justin N. Bottsford-Miller, et al. 
 
The abstract concludes: 
The combination of Vigil immunotherapy and checkpoint inhibitor atezolizumab in recurrent OvC demonstrated safety and suggest a lower toxicity profile and a significant OS advantage in recurrent BRCA1/2-wt OvC patients treated with Vigil first followed by the combination of Vigil and Atezolizumab. Clinical trial information: NCT03073525.

-------------------------------------------------------------------------------------------------------------------------------------------------------

 
Jonathan Wade Goldman, Sarina Anne Piha-Paul, Brendan D. Curti, et al.
 
The abstract concludes: 
The safety profile of MEDI0562 in combination with durva or treme was similar between groups. Clinical activity was observed with MEDI0562 + durva in pts with advanced solid tumors. Clinical trial information: NCT02705482.

-------------------------------------------------------------------------------------------------------------------------------------------------------

 
Jason J. Luke, Manish R. Patel, Erika Paige Hamilton, et al.
 
The abstract concludes: 
MGD013, a novel molecule designed to coordinately block PD-1 and LAG-3, has demonstrated an acceptable safety profile and encouraging early evidence of anti-tumor activity. Clinical trial information: NCT03219268.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, et al.
 
The abstract concludes: 
CX-072 monotherapy demonstrated durable responses consistent with activation of the PROBODY therapeutic in the TME. The safety profile supports the tolerability of CX-072 as monotherapy and when combined with IPI3. CX-072 + IPI3 demonstrated activity in heavily pretreated pts with various tumors. The safety profile of the combination of CX-072 with IPI3 compares favorably to historical data (grade ≥3 TRAEs 55% and leading to dc in 36%; Larkin J, et al. N Engl J Med. 2015;373:23-34). CX-072 + IPI3 is being explored in a phase 2 study in 2L melanoma Clinical trial information: NCT03993379.
François Ghiringhelli, Benoist Chibaudel, Julien Taieb, Jet al.
 
The abstract concludes: 
The interim safety analysis has supported safety and efficacy of the MEDITREME regimen in first- line MCRC. Finally, results will be presented after maturation of follow up. Clinical trial information: NCT03202758.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Landon Carter Brown, Ramy Sedhom, Eric B Schwartz, et al.
 
The abstract concludes: 
This multicenter study shows impressive and durable objective response rates to ICI for patients harboring pathogenic LRP1B alterations when compared to those with LRP1B VUS, independent of TMB/MSI status. Further mechanistic insights and prospective validation studies are warranted.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Benjamin Garmezy, Jinesh S. Gheeya, Kyaw Zin Thein, et al. 
 
The abstract concludes: 
Pathogenic POLE mutations were associated with clinical benefit to ICI therapy. Further studies are warranted to validate POLE mutations as a predictive biomarker. Multiple co-occurring DNA damage response mutations were found, which may contribute to ICI clinical benefit.
--------------------------------------------------------------------------------------------------------------------------------------------------------
 

3032 CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.

Hans Prenen, Jeroen Dekervel, Sébastien Anguille, et al.

The abstract concludes:

These early clinical results demonstrate the safety and tolerability of a non-gene edited predominantly CD4+ CAR-T therapeutic approach. The initial observations of clinical activity in metastatic CRC patients warrants the continued development of this therapy. Clinical trial information: NCT03692429.

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
MORE ABSTRACTS: